TIAP FEATURES: Vasomune Therapeutics – Tackling Vascular Dysfunction and Boosting Host Defenses From viral and bacterial pneumonia and sepsis, to acute kidney injury, hemorrhagic shock, stroke, and complications associated with…
As part of Ontario’s Critical Technologies initiative, TIAP is pleased to be partnering with OBIO® to offer new support to accelerate the health science industry’s use of cutting-edge technologies. OBIO’s…
TIAP, University of Toronto, and Vector Institute Enter into New Collaboration Organizations bring together their DaRMoD and UTEST programs to help advance six emerging Ontario ventures Toronto Innovation Acceleration Partners…
TIAP Strengthens Leadership Team with Appointment of Prakash Gowd as Vice President Toronto Innovation Acceleration Partners (TIAP) is pleased to announce the appointment of Prakash Gowd MBA, BSc Pharm, C.Dir…
Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV Gates Foundation funding for an approach that leverages Radiant’s breakthrough Multabody™ platform TORONTO--(BUSINESS WIRE)--Radiant Biotherapeutics, a startup biotechnology company…
TIAP FEATURES: Zucara Therapeutics – Building on Canada’s Rich Research History to Dramatically Change Diabetes Disease Management “I think people know quite a bit about high blood sugar and the…
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies November 30, 2023 08:00 AM Eastern Standard Time TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--Phenomic AI Inc. (“Phenomic”), a…
TIAP and PRiME collaborate to accelerate next generation precision medicine ventures in Toronto TIAP and PRiME Next Generation Precision Medicine (PRiME) are pleased to announce their strategic partnership aimed at…
Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies - Agreement includes licensing options based on targets to be identified with Phenomic’s unique discovery…
AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care November 28th, 2023 Press Release Toronto, ON — AmacaThera, a leader in the development…